Navigation Links
ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver

rage us as we proceed expeditiously through our ongoing Phase 2 program."

Phase 1b Clinical Trial Design

This 14 day randomized, double-blind, placebo-controlled, sequential-group study of ascending multiple doses enrolled subjects with chronic HCV infection who were naive to treatment. Subjects were enrolled in sequential, ascending dose cohorts with a target of 16 subjects (12 subjects receiving HCV-796 BID and 4 receiving placebo in each cohort). The first cohorts assessed the effect of HCV-796 as monotherapy compared to placebo (data from which were released on November 10, 2005). Subsequent cohorts were comprised of subjects who received peg-IFN (PEG-Intron; 1.5 ug/kg/dose) on days -1 and 7 in combination with either placebo or HCV-796 (100 mg, 250 mg, 500 mg or 1000 mg) every 12 hours, from days 1 to 14.

Antiviral Activity Results

Data are available through treatment day 14 from subjects in four combination treatment groups (n= 10 to 12 subjects per group) and on 19 subjects who received peg-IFN alone.

-- For genotype 1, mean reduction from baseline ranged from 1.5 to 2.3 log10 on day 7 and from 2.6 to 3.2 log10 on day 14 in the combination therapy groups compared to 0.9 log10 on day 7 and 1.3 log10 on day 14 for peg-IFN alone.

-- For non-genotype 1, mean reduction from baseline ranged from 2.8 to 3.5 log10 on day 7 and from 3.5 to 4.8 log10 on day 14 in the combination therapy groups compared to 1.5 log10 on day 7 and 2.6 log10 on day 14 for peg-IFN alone.

-- Viral reduction greater or equal to 2.0 log10 at day 14 was achieved in 70 to 92 percent of subjects in all combination groups compared to 40 percent on peg-IFN alone.

-- At day 14, 30 to 33 percent of patients in the combination groups receiving greater than or equal to 250 mg BID of HCV-796 achieved viral levels below the quantification limit of 50 IU/mL HCV RNA.

Safety and Tolerability Results

A safety review of HCV-796 in combinati
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/22/2015)... May 22, 2015 The North American ... and is estimated to reach $90.7 million by 2019, at ... Browse through the TOC of North America Dental Lasers Market ... help of various tables and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ... on this report.   Dental lasers are ...
(Date:5/22/2015)...  The Mesothelioma Victims Center is incredibly passionate ... the best possible compensation, and they are also extremely ... cancer caused by exposure to asbestos or their ... treatment options such as a recent possible medical breakthrough. ... Center anytime at 866-714-6466. http://MesotheliomaVictimsCenter.Com ...
(Date:5/22/2015)... , May 22, 2015 Today, Rhodes ... nervous system stimulant indicated for the treatment of ... beginning Summer 2015. The announcement ... approval from the U.S. Food and Drug Administration ... extended-release formulation of methylphenidate capsule with an onset ...
Breaking Medicine Technology:North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
... May 31, 2012  Janssen Research & Development, LLC (Janssen), ... Application (NDA) to the U.S. Food and Drug Administration ... investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) ... 2 diabetes. The kidneys of people ...
... Therapeutics, Inc. (Nasdaq: OREX ) today announced that ... Global Healthcare Conference in New York. The presentation is scheduled ... Grand Hyatt New York. To listen to the live webcast ... Relations section of the Company,s website at www.orexigen.com . ...
Cached Medicine Technology:Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes 2Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes 3Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes 4
(Date:5/23/2015)... On May 13, Nithyananda Yoga Foundation organized a ... learned through meditation and initiation at Special Holistic School ... Yogamaatha, a nine-year-old girl from North Carolina, stunned an ... the 2015 Business Advocacy Summit at Capitol Hill in ... In a demonstration that lasted three hours, Yogamaatha was ...
(Date:5/23/2015)... CO (PRWEB) May 23, 2015 On May ... in MuckFest. The event was a 5k mud obstacle run ... more than 2 million people worldwide, and the reason we ... community,” said Chad Davis, owner of Farrell’s eXtreme Bodyshaping. “One-hundred ... Multiple Sclerosis Society.” , The event was not only attended ...
(Date:5/23/2015)... Add High-Quality prismatic refractions into footage using ProFlare ... simple as dragging and dropping footage into the FCPX timeline ... , Including over 80 stunning flares, ProFlare 5K Prism ... the ultimate bundle for adding prismatic refractions to any video. ... movie files designed for Final Cut Pro X, but are ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 The American ... exciting events in June. They will hold a webinar ... and a two-day class on Classical Chinese Medicine. , ... 3, Dr. Steve Given, the Dean of Clinical Education, ... the new First Professional Doctorate program. ACTCM is currently ...
(Date:5/22/2015)... Following yesterday’s announcement that Ascenta Health Limited has ... Nature’s Way, Marc St-Onge has affirmed his commitment to ... an integral part of the agreement with Nature’s Way ... develop Ascenta Skin into a leading player in the ... anti-aging skincare supplement featuring 6 active ingredients including therapeutic ...
Breaking Medicine News(10 mins):Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:ACTCM Announces Upcoming June Events 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2
... A Michigan State University surgeon is teaming up with ... create a simple, cost-effective saliva test to detect oral cancer, ... fewer people dying of the world,s sixth most common cancer. ... Medicine,s Department of Surgery and lead investigator on the project, ...
... TUESDAY, April 17 (HealthDay News) -- The ability to make ... changes in the brain,s white matter, a new imaging study ... 85, to perform a learning task involving money and also ... in decision-making are associated with the weakening of two specific ...
... Mothers with depression may behave in ways that disturb their ... University researchers conducted home visits with 45 mothers and their ... over 7 consecutive days to collect information about depression symptoms ... Greater amounts of sleep disruption were noted in infants whose ...
... TUESDAY, April 17 (HealthDay News) -- New research adds to ... (protein) plaques, the brain-clogging fragments that have been associated with ... Healthcare Berlin, researchers report that they were able to use ... the brains of patients whose Alzheimer,s was confirmed after death. ...
... HealthDay Reporter , TUESDAY, April 17 (HealthDay News) -- ... appear to get no survival benefit from adding the ... Cancer Institute report. An earlier trial had found ... patients aged 65 and older. Even so, the researchers ...
... drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small ... FDA in 2006 did not lead to significantly increase ... in Medicare, a new study by Dana-Farber Cancer Institute researchers ... April 18 Journal of the American Medical Association , ...
Cached Medicine News:Health News:Saliva test could dramatically increase detection of oral cancer 2Health News:Depressed Moms May Hinder Babies' Sleep 2Health News:New Method to Reveal Alzheimer's Marker Shows Promise 2Health News:Avastin No Benefit to Older Lung Cancer Patients: Study 2Health News:Avastin No Benefit to Older Lung Cancer Patients: Study 3Health News:Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients 2
... with 96-well plates in mind, Pipetman ... molecular biology applications: PCR* sequencing, immunology ... etc. Used with Diamond Tips from ... product will maximize performance and assure ...
... Finnpipette Focus multichannel ... dispensing of reagents into ... for 0.1-10 l volumes. ... of Finnpipette Focus multichannels, ...
... Long series in colonies, rows, and microplatesthat ... the multichannel pipette is becoming an ever-increasing ... use) was the main reason that the ... 8- or 12-channel pipette provides effective, precise, ...
... Focus multichannel pipettes speed ... reagents into microplates, with ... l volumes. The improved ... Focus multichannels, combined with ...
Medicine Products: